Johan Prevot has worked in the healthcare sector for 20 years in the field of health policy and patient advocacy.
Currently Mr. Prevot is the Executive Director of the International Patient Organisation for Primary Immunodeficiencies (IPOPI). As such he is responsible for the management and growth of IPOPI’s global activities, awareness and advocacy campaigns as well as the strengthening of IPOPI’s national member organisations network.
Johan Prevot previously worked as Director of Health Policy Europe for the Plasma Protein Therapeutics Association (PPTA), a trade association in the field of plasma protein therapies. Johan Prevot is also a Board member of the European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune diseases (ERN-RITA), Health First Europe (HFE) and the RECOMB research programme. He is also a Steering Committee Member of the Platform of Plasma Products Users (PLUS).
Johan Prevot has throughout his career been an advocate for improving patient access to early diagnosis and treatment in the field of rare plasma related disorders which include conditions such as primary immunodeficiencies, haemophilia and alpha 1 antitrypsin deficiency among others. Access to diagnosis and treatment for primary immunodeficiencies and other rare plasma related disorders varies greatly from country to country and many people living with these conditions in developing countries still nowadays can not access their life enhancing and/or life saving therapies. Mr Prevot has and continues to work closely with other stakeholder organisations sharing common objectives and priorities.